E
Elif Weidinger
Researcher at Ludwig Maximilian University of Munich
Publications - 34
Citations - 1164
Elif Weidinger is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Medicine & Tourette syndrome. The author has an hindex of 14, co-authored 30 publications receiving 872 citations.
Papers
More filters
Journal ArticleDOI
The role of inflammation in schizophrenia
TL;DR: Anti-inflammatory effects of antipsychotics, therapeutic effects of anti-inflammtory compounds, genetic, biochemical, and immunological findings point to a major role of inflammation in schizophrenia.
Journal ArticleDOI
Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium.
Gara Arteaga-Henríquez,Gara Arteaga-Henríquez,Maria S. Simon,Bianka Burger,Elif Weidinger,Annemarie J. M. Wijkhuijs,Volker Arolt,Tom K. Birkenhäger,Richard Musil,Norbert Müller,Hemmo A. Drexhage +10 more
TL;DR: The presence of inflammation in patients with MDD heralds a poor outcome of first-line antidepressant therapies, and immediate step-ups to dopaminergic or glutamatergic regimens or to (add-on) anti-inflammatory agents are most likely indicated.
Journal ArticleDOI
Impaired monocyte activation in schizophrenia.
Norbert Müller,Jenny Wagner,Daniela Krause,Elif Weidinger,Agnes Wildenauer,Michael Obermeier,Sandra Dehning,Rudolf Gruber,Markus J. Schwarz +8 more
TL;DR: The IL-1ß concentration was significantly lower in patients both before and after stimulation with polyI:C, and there was a trend towards a lower concentration after LPS stimulation.
Journal ArticleDOI
Anti-inflammatory treatment in schizophrenia
TL;DR: Growing evidence from clinical studies with COX-2 inhibitors points to favorable effects of anti-inflammatory therapy in schizophrenia, in particular in an early stage of the disorder.
Book ChapterDOI
The Role of Inflammation in Alzheimer’s Disease
TL;DR: The limitations and advantages of the protective effects of non-steroidal anti- inflammatory drugs (NSAIDs) and anti-inflammatory treatment options are discussed and possible future implications for AD therapy that might result from this underlying neuroinflammation are identified.